Interferon-γ-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis

Clinical and Experimental Immunology

Volumn 138, Issue 2, 2004, Pages 230-236

  Adikari, S B ^a,c   Lian, H ^a   Link, H ^a,b   Huang, Y M ^a   Xiao, Bao Guo ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF PERADENIYA   (Sri Lanka)

^d FUDAN UNIVERSITY   (China)

Author keywords

1 MT; Dendritic cells; EAMG; IDO; IFN

Indexed keywords

1 METHYL DEXTRO TRYPTOPHAN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; NICOTINIC RECEPTOR; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL COUNT; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; FEMALE; IMMUNIZATION; LYMPH NODE; LYMPHOCYTE FUNCTION; MONONUCLEAR CELL; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN;

ANIMALS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL DIVISION; DENDRITIC CELLS; FEMALE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; MEMBRANE PROTEINS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; SPLEEN; T-LYMPHOCYTES; TRYPTOPHAN; TRYPTOPHAN OXYGENASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8144224918     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02585.x     Document Type: Article

References (26)

1. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357:2122-8.
2. Palace J, Vincent A, Beeson D. Myasthenia gravis: diagnostic and management dilemmas. Curr Opin Neurol 2001; 14:583-9.
3. Link H, Xiao BG. Rat models as tool to develop new immunotherapies. Immunol Rev 2001; 184:117-28.
4. Xiao BG, Duan RS, Link H et al. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell Immunol 2003; 223:63-9.
5. Kadowaki N. Immunotherapy exploiting the versatility of dendritic cells. Ther Apher Dial 2003; 7:312-7.
6. Ichim TE, Zhong R, Min WP. Prevention of allograft rejection by in vitro generated tolerogenic dendritic cells. Transpl Immunol 2003; 11:295-306.
7. Dhodapkar MV, Steinman RM, Krasovsky J et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193:233-8.
8. Xiao BG, Wu XC, Yang JS et al. Therapeutic potential of IFN-γ-modified dentritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol 2004; 16:13-22.
9. Mahnke K, Qian Y, Knop J, Enk AH. Dendritic cells, engineered to secrete a T-cell receptor mimic peptide, induce antigen-specific immunosuppression in vivo. Nat Biotechnol 2003; 21:903-8.
10. Zhang GX, Kishi M, Xu H, Rostami A. Mature bone marrow-derived dendritic cells polarize Th2 response and suppress experimental autoimmune encephalomyelitis. Multiple Sclerosis 2002; 8:463-8.
11. Lindstrom J, Einarson B, Tzartos S. Production and assay of antibodies to acetylcholine receptors. Meth Enzymol 1981; 74:432-60.
12. Deibler GE, Martenson RE, Kies MW. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem 1972; 2:139-65.
13. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
14. Crowley M, Inaba K, Witmer-Pack M, Steinman RM. The cell surface of mouse dendritic cells: FACS analysis of dendritic cells from different tissues including thymus. Cell Immunol 1989; 118:108-25.
15. Brenan M, Puklavec M. The MRC OX-62 antigen: a useful marker in the purification of rat veiled cells with the biochemical properties of an intergrin. J Exp Med 1992; 175:1457-65.
16. 3H]thymidine incorporation assay. J Immunol Meth 1994; 170:211-24.
17. Zhang GX, Xiao BG, Bai XF et al. Mice with IFN-γ-receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 1999; 162:3775-81.
18. Zhong C, Li WZ, Lu L. In vivo migration and survival of donor-derived dendritic cell progenitors genetically modified using an adenoviral vector encoding cDNA for TGF beta 1. Zhonghua Yi Xue Za Zhi 1999; 79:174-7.
19. Sarkhosh K, Tredget EE, Karami A et al. Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG). J Cell Biochem 2003; 90:206-17.
20. Munn DH, Shafizadeh E, Attwood JT et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189:1363-72.
21. Widner B, Ledochowski M, Fuchs D. Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr Drug Metab 2000; 1:193-204.
22. Robinson CM, Shirey KA, Carlin JM. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res 2003; 23:413-21.
23. Sakurai K, Zou JP, Tschetter JR et al. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 129:186-96.
24. MacLennan I, Vinuesa C. Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. Immunity 2002; 17:235-8.
25. Do RK, Chen-Kiang S. Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev 2002; 13:19-25.
26. Nardelli B, Belvedere O, Roschke V et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97:198-204.